New drug combo may make bone marrow transplants safer for blood cancer patients
NCT ID NCT04395222
First seen Jan 08, 2026 · Last updated Jun 15, 2026 · Updated 23 times
Summary
This study tests whether replacing a standard immune-suppressing drug with tocilizumab can prevent graft failure and graft-versus-host disease in blood cancer patients receiving a special type of bone marrow transplant. About 21 adults with high-risk blood cancers are participating. The goal is to improve immune recovery and reduce cancer relapse while keeping transplant complications low.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medical College
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.